248 related articles for article (PubMed ID: 21519056)
21. Low procedure-related mortality achieved with alcohol septal ablation in European patients.
Veselka J; Jensen MK; Liebregts M; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Bundgaard H; Steggerda R; Faber L
Int J Cardiol; 2016 Apr; 209():194-5. PubMed ID: 26896622
[No Abstract] [Full Text] [Related]
22. A modified method (MK method) of alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopahty.
Kawase Y; Matsuo H
Catheter Cardiovasc Interv; 2016 Nov; 88(6):1002-1005. PubMed ID: 26577494
[TBL] [Abstract][Full Text] [Related]
23. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
Nielsen CD; Fernandes V; Spencer WH
Am Heart Hosp J; 2003; 1(1):83-90. PubMed ID: 15785181
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy.
Mitsutake R; Miura S; Sako H; Nishikawa H; Saku K
Int J Cardiol; 2008 Sep; 129(2):e61-3. PubMed ID: 17888532
[TBL] [Abstract][Full Text] [Related]
25. "Moving left ventricular obstruction" due to stress cardiomyopathy in a patient with hypertrophic obstructive cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.
Akita K; Maekawa Y; Tsuruta H; Okuda S; Yanagisawa R; Kageyama T; Kawakami T; Kanazawa H; Hayashida K; Yuasa S; Murata M; Jinzaki M; Fukuda K
Int J Cardiol; 2016 Jan; 202():194-5. PubMed ID: 26397409
[No Abstract] [Full Text] [Related]
26. Myocardial mechanics explains the time course of benefit for septal ethanol ablation for hypertrophic cardiomyopathy.
Carasso S; Woo A; Yang H; Schwartz L; Vannan MA; Jamorski M; Linghorne M; Wigle ED; Rakowski H
J Am Soc Echocardiogr; 2008 May; 21(5):493-9. PubMed ID: 17961980
[TBL] [Abstract][Full Text] [Related]
27. Identifying the target septal perforator prior to alcohol septal ablation in hypertrophic obstructive cardiomyopathy: a new application for computed tomography coronary angiography.
Spratt JC; Langrish JP
Heart; 2011 Oct; 97(20):1718-9. PubMed ID: 21807658
[No Abstract] [Full Text] [Related]
28. Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Transcoronary and Endocardial Approach.
Aksu T; Guler T; Yalin K; Golcuk SE; Ozcan K
Am J Med Sci; 2016 Nov; 352(5):466-471. PubMed ID: 27865293
[TBL] [Abstract][Full Text] [Related]
29. Tools & techniques: Alcohol septal ablation for hypertrophic cardiomyopathy.
Bertog SC; Franke J; Hornung M; Hofmann I; Sievert H
EuroIntervention; 2011 Dec; 7(8):1004-5. PubMed ID: 22157484
[No Abstract] [Full Text] [Related]
30. Substitution of ethanol with specially designed microspheres in a TASH procedure.
Latsios G; Gerckens U; Mueller R; Grube E
EuroIntervention; 2011 Feb; 6(7):889-92. PubMed ID: 21252025
[TBL] [Abstract][Full Text] [Related]
31. Surgical management of obstructive hypertrophic cardiomyopathy: the gold standard.
Brown ML; Schaff HV
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):715-22. PubMed ID: 18510487
[TBL] [Abstract][Full Text] [Related]
32. The less-is-better effect: The case of alcohol dose in septal ablation for hypertrophic cardiomyopathy.
Pelliccia F; Pasceri V
Int J Cardiol; 2021 Jun; 333():143-144. PubMed ID: 33812948
[No Abstract] [Full Text] [Related]
33. Conservative versus invasive treatment in hypertrophic obstructive cardiomyopathy: an echocardiography study.
Honek T; Krejci J; Machal J; Groch L; Sitar J; Meluzin J; Spinarova L
Bratisl Lek Listy; 2016; 117(10):562-570. PubMed ID: 27826970
[TBL] [Abstract][Full Text] [Related]
34. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy.
Gietzen FH; Leuner CJ; Raute-Kreinsen U; Dellmann A; Hegselmann J; Strunk-Mueller C; Kuhn HJ
Eur Heart J; 1999 Sep; 20(18):1342-54. PubMed ID: 10462469
[TBL] [Abstract][Full Text] [Related]
35. 4D Computed Tomography Visualization of Effective Septal Reduction After Alcohol Septal Ablation for Fatal Hypertrophic Obstructive Cardiomyopathy.
Akita K; Kaneko Y; Sato R; Iguchi K; Suwa K; Maekawa Y
Circ J; 2022 Mar; 86(4):725. PubMed ID: 34853278
[No Abstract] [Full Text] [Related]
36. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy.
Monakier D; Woo A; Puri T; Schwartz L; Ross J; Jamorski M; Yang H; Liu Z; Vannan M; Wigle ED; Rakowski H
Am J Cardiol; 2004 Dec; 94(12):1515-22. PubMed ID: 15589007
[TBL] [Abstract][Full Text] [Related]
37. [Non-pharmacological treatment of hypertrophic obstructive cardiomyopathy guided by echocardiography].
La Canna G; Montorfano M; Ficarra E; Michev I; Capritti E; Grimaldi A; De Cobelli F; Verzini A; Colombo A; Alfieri O
G Ital Cardiol (Rome); 2006 Mar; 7(3):192-205. PubMed ID: 16572985
[TBL] [Abstract][Full Text] [Related]
38. Surgical septal myectomy versus septal alcohol ablation for hypertrophic obstructive cardiomyopathy.
Efthimiadis GK; Meditskou S; Vassilikos V; Hadjimiltiades S; Styliadis IH; Parcharidis GE
Swiss Med Wkly; 2008 May; 138(21-22):322; author reply 322-3. PubMed ID: 18578089
[No Abstract] [Full Text] [Related]
39. Myectomy for hypertrophic obstructive cardiomyopathy after failed alcohol septal ablation: clinicopathological correlations.
Arrazaghi AA; Butany JW; Williams WG; Wigle DE; Rakowski H
Can J Cardiol; 2001 Feb; 17(2):197-202. PubMed ID: 11223490
[TBL] [Abstract][Full Text] [Related]
40. New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence.
Maron BJ
Eur Heart J; 1999 Sep; 20(18):1292-4. PubMed ID: 10462461
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
